PACT Pharma Overview

  • Founded
  • 2016
Founded
  • Status
  • Private
  • Employees
  • 195
Employees
  • Latest Deal Type
  • Series C
  • Latest Deal Amount
  • $75M
Latest Deal Amount
  • Investors
  • 13

PACT Pharma General Information

Description

Developer of personalized adoptive T cell therapies designed to re-program the immune system to target and eradicate cancer. The company's therapies help in the identification of neo-epitopes that serve as private mutations for cancer and creates an opportunity to engineer autologous T cells that target and kill tumors expressing these neo-antigens, enabling physicians to recognize and remove each patient's cancer cells.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 2 Corporate Drive
  • South San Francisco, CA 94080
  • United States
+1 (650) 000-0000

PACT Pharma Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

PACT Pharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC (Series C) 10-Jan-2020 $75M 00000 00000 Completed Clinical Trials - Phase 1
2. Early Stage VC (Series B) 25-May-2018 0000 00000 00000 Completed Clinical Trials - Phase 1
1. Early Stage VC (Series A) 20-Dec-2016 $31.7M $31.7M 000.00 Completed Clinical Trials - Phase 1
To view PACT Pharma’s complete valuation and funding history, request access »

PACT Pharma Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 000
Series B 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series A 29,999,999 $0.000100 $0.08 $1 $1 1x $1 20.47%
To view PACT Pharma’s complete cap table history, request access »

PACT Pharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of personalized adoptive T cell therapies designed to re-program the immune system to target and eradicate can
Drug Discovery
South San Francisco, CA
195 As of 2021
00000
0000 0000-00-00
00000000000 00000

00000000

ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolor
0000000000000
Gaithersburg, MD
00 As of 0000
00000
0000 0000-00-00
00000000 00000

000000 0

ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse
0000 000000000
Redwood City, CA
00 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

PACT Pharma Competitors (17)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
NexImmune Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
000000 00000000000 Venture Capital-Backed Redwood City, CA 00 00000 000000000 00000
00000 000000000000 Formerly VC-backed Waltham, MA 00 00000 00000000 00000
000000000 00000000 Venture Capital-Backed Austin, TX 00 000.00 0000000000 0 000.00
0000000 000000000 Venture Capital-Backed Cambridge, MA 00 000.00 000000 - 000 000.00
You’re viewing 5 of 17 competitors. Get the full list »

PACT Pharma Executive Team (12)

Name Title Board Seat Contact Info
Scott Garland Chief Executive Officer
Timothy Moore Chief Operating Officer & President
Kyle Lapham Chief Technology Officer
Ashish Kheterpal Chief Information Officer
Atulya Agarwal JD Chief Legal and Compliance Officer
You’re viewing 5 of 12 executive team members. Get the full list »

PACT Pharma Board Members (8)

Name Representing Role Since
Antoni Ribas MD Self Co-Founder, Member of Scientific Advisory Board & Board Member 000 0000
Blake Byers Ph.D Self Chairman 000 0000
Helen Kim Vida Ventures (Boston) Board Member 000 0000
James Heath Ph.D PACT Pharma Co-Founder, Board Member & Member of Scientific Advisory Board 000 0000
KT Moortgat Ph.D AbbVie Ventures Board Observer 000 0000
You’re viewing 5 of 8 board members. Get the full list »

PACT Pharma Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

PACT Pharma Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Lyell Corporation Minority 000 0000 000000 0
Vida Ventures (Boston) Venture Capital Minority 000 0000 000000 0
AbbVie Ventures Corporate Venture Capital Minority 000 0000 000000 0
Canaan Partners Venture Capital Minority 000 0000 000000 0
Casdin Capital Hedge Fund Minority 000 0000 000000 0
You’re viewing 5 of 13 investors. Get the full list »

PACT Pharma Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000 000000 07-Oct-2016 00000 00000 00 000000 Drug Discovery
To view PACT Pharma’s complete investments history, request access »